PMID: 8941672Dec 1, 1996Paper

MHC class I expression on dendritic cells is sufficient to sensitize for transplantation immunity

The Journal of Investigative Dermatology
P LenzP R Bergstresser

Abstract

The immunogenicity of an allograft correlates with the number of MHC class II+ antigen-presenting cells (dendritic cells) that it contains. To determine whether these antigen-presenting cells induce not only MHC class II-mediated immune responses, but also physiologically relevant levels of MHC class I immunity, we took advantage of a unique MHC class I+/class II-/CD80+ dendritic cell line (80/1 DC) derived from murine (C3H, H-2k) fetal skin. The 80/1 DC sensitized H-2-disparate recipients for specific transplantation immunity, as evidenced by significantly accelerated rejection (second set) of skin allografts from C3H mice, but not of third-party allografts. As few as 10(2) 80/1 DC, administered by the subcutaneous route, were effective, indicating their high potency as stimulator cells. Several lines of evidence support the hypothesis that the immunization observed was mediated primarily by direct presentation of allo-class I: (i) Blockage of the co-stimulatory molecule CD80 on 80/1 DC abrogated their sensitizing capacity; (ii) equal numbers of a nonprofessional antigen-presenting cell line (L929, C3H origin) as well as dead 80/1 DC failed to accelerate graft rejection; and (iii) injection of syngeneic (BALB/c) Langerhans cel...Continue Reading

Citations

Apr 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P LenzJ T Schiller
Apr 16, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Nada KanaanMatthew D Griffin
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tamara KoppGeorg Stingl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.